A new aside by Janssen quest & Development, LLC informs that they have unblinded the Phase 3 study, COU-AA-302, which shows that Zytiga (abiraterone acetate), when taken beside prednisone, is productive in treating mildly symptomatic or asymptomatic work who are distress from metastatic castration-resistant prostate cancer (CRPC) and have not gone through chemotherapy. as concerned with Zytiga, which was approved by the U.S Food and Drug supervision (FDA) in 2011, William N. Hait, MD, PhD, from Global Head, Janssen R&D commented: "Since its first validate
roget's ii: the new thesaurusmain entry:acceptance
part of speech:noun
approbation in the U...
More: - From the site